Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 15, 2009, Pages 2399-2406

  Huang, Huiqiang ^a   Cai, Qingqing ^a   Lin, Tianxin ^a   Lin, Xubin ^a   Liu, Yushan ^a   Gao, Yan ^a   Peng, Ruiqing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Autologous hematopoietic stem cell transplantation; Hepatitis B reactivation; High dose chemotherapy; Lamivudine; Non hodgkin's lymphoma

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MELPHALAN;

ADULT; ADVANCED CANCER; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; INFECTION PREVENTION; MALE; MORTALITY; MUTATION; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PILOT STUDY; RELAPSE; TREATMENT DURATION; VIRUS REACTIVATION; WHOLE BODY RADIATION;

ADULT; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; INCIDENCE; LAMIVUDINE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 70349379916     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903251710     Document Type: Article

References (31)

1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545
2. Pettengell R, Radford JA, Morgenstern GR, et al. Survival benefit from high-dose therapy with autologous blood progenitor cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol 1996;14:586-592 (Pubitemid 126424031)
3. Cortelazzo S, Rossi A, Bellavita P, et al. Clinical outcome after autologous transplantation in non-Hodgkin's lymphoma patients with high international prognostic index (IPI). Ann Oncol 1999;10:427-432 (Pubitemid 29236420)
4. Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287-1295 (Pubitemid 38375363)
5. Wang F, Xu RH, Han B, etal. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer 2007;109:1360-1364
6. Chen MH, Hsiao LT, Chiou TJ, et al. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma. Ann Hematol 2008;87:475-480
7. Ozguroglu M, Bilici A, Turna H, etal. R eactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma. Med Oncol 2004;21:67-72
8. Li YH, He YF, Wang FH, etal. Clinical analysis of liver damage of 116 malignant lymphoma patients with chronic HBV infection after cytotoxic chemotherapy. Ai Zheng 2005;24:1507-1509
9. Lau GKK, Liang R, Chiu EKW, et al. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant 1997;19:795-799 (Pubitemid 27207895)
10. Seth P, Alrajhi AA, Kagevi I, et al. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant 2002;30:89-94 (Pubitemid 34993859)
11. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661 (Pubitemid 26001954)
12. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B: Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-68
13. Andreone P, Caraceni P, Grazi GL, et al. Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol 1998;29:985-989 (Pubitemid 28559069)
14. Lau GK, Yiu HH, Fong DY, etal. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-1749
15. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927-934 (Pubitemid 41103605)
16. Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006;24:1003-16 • An interesting review discussing the role of lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection.
17. Li YH, He YF, Jiang WQ, etal. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006;106:1320-1325
18. Hsu C, Hsiung CA, Su IJ, etal. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008;47:844-53 • A randomized trial to compare prophylactic or therapeutic lamivudine use for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma.
19. NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphoma. Available from: http://www.nccn.org [Last accessed 25 November 2008]
20. Lau GKK, He ML, Fong DYT, et al. Preemptive use of lamivudine reduced hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36:702-9 • A non-randomized trial comparing preemptive use of lamivudine or non-use of antiviral therapy's hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.
21. Lok AS, McMahon BJ. Chronic hepatitis B update of recommendations. Hepatology 2004;39:857-861
22. Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002;3:333-340 (Pubitemid 34661982)
23. Shibolet O, Ilan Y, Gillis S, et al. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002:100:391-396 (Pubitemid 34761098)
24. Loomba R, Liang TJ. Novel approaches to new therapies for hepatitis B virus infection. Antivir Ther 2006;11:1-15 (Pubitemid 43306072)
25. De Franchis R, Hadengue A, Lau G, et al. EASL Jury. EASL International Consensus Conference on Hepatitis B. 13 - 14 September 2002, Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003;39(Suppl 1):S3-25
26. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-28 •• An interesting review discussing the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.
27. Zhong S, Yeo W, Schroder C, et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 2004;11:55-59 (Pubitemid 38221618)
28. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539
29. Ling R, Mutimer D, Ahmed N, et al. Selection of mutation in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-713 (Pubitemid 26296020)
30. Rivkin A. A review of entecavir in the treatment of chronic hepatitis B infection. Curr Med Res Opin 2005;21:1845-1856 (Pubitemid 41667253)
31. Endo T, Sakai T, Fujimoto K, etal. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2001;27:433-6 •• The first case report discussing a possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. (Pubitemid 32201352)